Arterial Stiffness and Heart Pumping Problems in Heart Failure Risk
Studies whether stiff arteries predict heart filling problems in adults at risk of HFpEF.
Plain-language title generated from the registry record
Registry title: Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF
Key facts
- Where
- Göttingen, GermanySee the site
Where in Germany
- Universitätsmedizin GöttingenGöttingen, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Medical Center Goettingen
- Trial code
- NCT06208007
- Record updated
- 9 May 2024
- Original description
Patients at risk for developing heart failure with preserved ejection fraction (HFpEF) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave analysis to investigate the association of arterial stiffening and the development of cardiac diastolic dysfuntion and HFpEF.Read full original descriptionShow less
Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF
Patients at risk for developing heart failure with preserved ejection fraction (HFpEF) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave analysis to investigate the association of arterial stiffening and the development of cardiac diastolic dysfuntion and HFpEF.
Inclusion: One or more of the following criteria:; Age > 60 years; Arterial hypertension (RR systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg or ≥ 2 antihypertensive drugs); Diabetes mellitus Type I or II; Atrial fibrillation; Chronic kidney disease (GFR < 60 ml/min/1,73 m2 or urine albumin ≥ 30mg/24h or ACR ≥ 30 mg/g); BMI ≥ 30 kg/m2; NYHA ≥ II; E/e' > 8.
Exclusion: Significant valve disease (Grade III or higher); History of interventional or surgical valve repair; Respiratory diseases as a known cause for dyspnea; Hypertrophic/restrictive/arrhythmogenic/dilatative cardiomyopathies including cardiac amyloidosis or sarcoidosis and toxic cardiomyopathy; History of heart transplantation; Left ventricular ejection fraction < 50 %; Regional wall motion abnormalities; Atrial flutter or fibrillation during examination.